Literature DB >> 26699688

Biliary tract cancer registry in Japan from 2008 to 2013.

Shin Ishihara1, Akihiko Horiguchi2, Shuichi Miyakawa3, Itaru Endo4, Masaru Miyazaki5, Tadahiro Takada6.   

Abstract

BACKGROUND: The present study analyzed biliary tract cancer patients registered from 2008 to 2013 in Japan and evaluated the outcomes of biliary tract cancer.
METHODS: A total of 18,606 patients were registered from 2008 to 2013. Cases were analyzed with regard to patient survival according to contiguous extent of the primary tumor (T), node metastasis, and tumor stage using the 3rd English edition of the Japanese classification of the biliary tract cancers.
RESULTS: Five-year survival rates were 39.8% for gallbladder cancer, 24.2% for perihilar bile duct cancer, 39.1% for distal bile duct cancer, and 61.3% for ampullary region cancer. Significant differences were observed between newly introduced subdivisions in the new Japanese classification for all tumoral sites except gallbladder cancer. The survival rate in patients with #13a metastasis was significantly higher than in patients with distant lymph node metastasis.
CONCLUSIONS: The new Japanese classification adopted the 7th edition of staging system developed by the Union for International Cancer Control staging system. However, numerous aspects of these classification systems remain unvalidated. The present analysis demonstrated the significance of a proportion of T factor subdivisions and classifications of regional lymph nodes in cases of gallbladder cancer in the new Japanese classification.
© 2016 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Biliary tract cancers; Japanese classification; Lymph node metastasis; Stage of disease; UICC staging system

Mesh:

Year:  2016        PMID: 26699688     DOI: 10.1002/jhbp.314

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  28 in total

1.  Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.

Authors:  Kohei Nakachi; Masaru Konishi; Masafumi Ikeda; Kazuaki Shimada; Takuji Okusaka; Akio Saiura; Hiroshi Ishii; Masanori Sugiyama; Junji Furuse; Hirohiko Sakamoto; Tomotaka Shimamura; Takehiro Ohta
Journal:  Int J Clin Oncol       Date:  2018-04-28       Impact factor: 3.402

2.  Changing Odds of Survival Over Time among Patients Undergoing Surgical Resection of Gallbladder Carcinoma.

Authors:  Stefan Buettner; Georgios Antonios Margonis; Yuhree Kim; Faiz Gani; Cecilia G Ethun; George A Poultsides; Thuy Tran; Kamran Idrees; Chelsea A Isom; Ryan C Fields; Bradley Krasnick; Sharon M Weber; Ahmed Salem; Robert C G Martin; Charles R Scoggins; Perry Shen; Harveshp D Mogal; Carl Schmidt; Eliza Beal; Ioannis Hatzaras; Rivfka Shenoy; Shishir K Maithel; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2016-08-05       Impact factor: 5.344

3.  Over 700 Whipples for Pancreaticobiliary Malignancies: Postoperative Morbidity Is an Additional Negative Prognostic Factor for Distal Bile Duct Cancer.

Authors:  Stefano Andrianello; Giovanni Marchegiani; Giuseppe Malleo; Borislav Chavdarov Rusev; Aldo Scarpa; Deborah Bonamini; Laura Maggino; Claudio Bassi; Roberto Salvia
Journal:  J Gastrointest Surg       Date:  2016-11-23       Impact factor: 3.452

4.  Role of adjuvant (chemo)radiotherapy for resected extrahepatic cholangiocarcinoma: a meta-analysis.

Authors:  Xin-Qi Shi; Jing-Yu Zhang; Hua Tian; Ling-Na Tang; Ai-Lin Li
Journal:  J Zhejiang Univ Sci B       Date:  2020-07       Impact factor: 3.066

5.  Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.

Authors:  Ryusei Matsuyama; Ryutaro Mori; Yohei Ota; Yuki Homma; Yasuhiro Yabusita; Seigo Hiratani; Takashi Murakami; Yu Sawada; Kentaro Miyake; Yasuhiro Shimizu; Takafumi Kumamoto; Itaru Endo
Journal:  Ann Surg Oncol       Date:  2022-01-07       Impact factor: 5.344

Review 6.  Cholangiocarcinoma: a site-specific update on the current state of surgical management and multi-modality therapy.

Authors:  Michael K Turgeon; Shishir K Maithel
Journal:  Chin Clin Oncol       Date:  2019-09-02

Review 7.  Current Status on Cholangiocarcinoma and Gallbladder Cancer.

Authors:  Tomoki Ebata; Giorgio Ercolani; Domenico Alvaro; Dario Ribero; Luca Di Tommaso; Juan W Valle
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

8.  Prognostic Impact of Extracapsular Lymph Node Invasion and Myofibroblastic Activity in Extrahepatic Bile Duct Cancer.

Authors:  Tadashi Yoshizawa; Keinosuke Ishido; Kensuke Saito; Toshihiro Haga; Hiroko Seino; Yunyan Wu; Satoko Morohashi; Kenichi Hakamada; Hiroshi Kijima
Journal:  Clin Med Insights Pathol       Date:  2017-09-06

9.  Outcome and evaluation of prognostic factors after pancreaticoduodenectomy for distal cholangiocarcinoma.

Authors:  Johannes Byrling; Roland Andersson; Agata Sasor; Gert Lindell; Daniel Ansari; Johan Nilsson; Bodil Andersson
Journal:  Ann Gastroenterol       Date:  2017-06-20

10.  Extracellular vesicle-shuttled miRNAs as a diagnostic and prognostic biomarker and their potential roles in gallbladder cancer patients.

Authors:  Eijiro Ueta; Koichiro Tsutsumi; Hironari Kato; Hiroshi Matsushita; Hidenori Shiraha; Masakuni Fujii; Kazuyuki Matsumoto; Shigeru Horiguchi; Hiroyuki Okada
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.